Bank of America has dropped 4.6% on the week to $59.52, and the options market has noticed — put demand has spiked to its most defensive reading in months, even as short sellers continue to quietly reduce exposure.
The clearest shift this week is in options positioning. Put/call ratio jumped to 1.38 on September 15, running more than 2.5 standard deviations above its 20-day average of 1.21. That is the most elevated z-score in the recent history of this dataset, and while the ratio remains well below the 52-week high of 1.67, the speed of the move matters. From September 11 through September 15, the PCR climbed steadily as the stock fell — a pattern consistent with investors buying downside protection into the October 14 earnings window rather than outright directional bets. The stock has now shed 7.7% over the past month, adding urgency to that hedging impulse.
Short interest tells the opposite story. Despite the price weakness, the short book continued shrinking — shares short fell another 3.9% on the week to 80.6 million, equivalent to just 1.10% of free float. That is a continuation of the trend documented in recent notes: three separate short-building episodes across the quarter, each ending in covering, with the current level now the lowest in the 90-day tracked window. Lending conditions offer zero support for a short thesis. Borrow availability is effectively unlimited, with over 5 billion shares available against a short book of 80 million. Cost to borrow eased 12% on the week to just 0.34%. Shorts who want the position face no friction; they simply are not building it.
The Street remains firmly constructive, and has been since the July earnings beat drove a broad round of target upgrades. Most major firms lifted targets in mid-July following the Q2 print — Barclays to $72, Wells Fargo to $69, UBS to $70, JP Morgan to $68 — all while maintaining positive ratings. The consensus mean target is $68.86 against a current price of $59.52, implying roughly 16% upside. That gap has widened materially this week purely because the stock has sold off, not because the Street has moved. The bull case rests on 7.2% revenue growth and a 9% rise in net interest income. Bears point to a CET1 ratio that slipped to 11.2% and a supplementary leverage ratio down 20 basis points to 5.5% — capital headwinds that may constrain buyback and growth flexibility heading into a tougher macro backdrop. Price-to-book has contracted 9% over the past 30 days to 1.40x, and the PE multiple has compressed nearly a full turn to 11.6x over the same period.
One institutional angle worth noting: Berkshire Hathaway's last disclosed stake was 483 million shares, or 6.9% of shares outstanding — but the most recent 13G/A on file for Warren Buffett (filed November 2025) showed a reduction from 8.9% to 7.8%. The disclosure caveat applies here: 13D/G positions are event-driven around the 5% threshold, and current holdings may differ materially from the last filing. Whether Berkshire has continued trimming into this year's rally is unknown. BlackRock remains the largest disclosed holder at 7.8% of shares, adding roughly 6.4 million shares in the most recent reporting period.
The next hard date is October 14. The July Q2 report produced a 3.5% one-day gain and a 2.9% five-day follow-through — the most recent comparable data point in the earnings history. Whether defensive options positioning resolves before or after that print, and whether the stock can reclaim the $62–63 range where shorts were previously covering, are the two things worth tracking into month-end.
See the live data behind this article on ORTEX.
Open BAC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
